Stem Cell Biology and Regenerative Medicine
Matthew Kalady, M.D.
Lerner Research Institute
9500 Euclid Avenue
Cleveland, Ohio 44195
Phone: (216) 445-7694
Fax: (216) 636-5454
The laboratory broadly focuses on the biology of sporadic and hereditary colon and rectal cancer development, progression, and response to therapy. Colon and rectal cancers are a clinically heterogeneous group with variable prognosis and outcomes that are determined by underlying molecular and genetic changes. Using advanced high-throughput technology, the laboratory has developed gene signature profiles to help predict disease recurrence and response to medical therapies. Specific projects include the use of gene expression signatures to predict recurrent rectal cancer, the study of gene expression changes in response to chemotherapy and radiation, differential gene expression between primary tumor and metastatic deposits, and analysis of expression patterns to provide more accurate cancer staging. We have used the information gained from these studies to identify key pathways and mechanisms involved in tumor resistance to chemotherapy and radiation, including the role of colorectal cancer stem cells. Using in vitro cell culture and an in vivo colorectal cancer mouse xenograft models, the laboratory is studying novel therapy combinations and interventions to help increase tumor response to treatment.
Lead Research Technologist
Sylvain Ferrandon Ph.D.
Postdoctoral Research Fellow
Nneha Sakre Ph.D.
- Kalady MF, DeJulius K, Sanchez JA, Jarrar A, Liu X, MD, Manilich E, Skacel M, Church JM. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012 Feb;55(2):128-33.
- Kalady MF, Coffey JC, Dejulius K, Jarrar A, Church JM. High-throughput arrays identify distinct genetic profiles associated with lymph node involvement in rectal cancer. Dis Colon Rectum. 2012 Jun;55(6):628-39.
- Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF, Church JM, Ting AH. Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Res. 2012 Feb;22(2):283-91.
- Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF, Willis J, Moore JH, Tesar PJ, Laframboise T, Markowitz S, Lupien M, Scacheri PC. Epigenomic enhancer profiling defines a signature of colon cancer. Science. 2012 May 11;336(6082):736-9.